82
5
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181
Nickalls RW, Nickalls EA (1988) The first use of physostigmine in the treatment of atropine poisoning. A
translation of Kleinwachter’s paper entitled 'Observations on the effect of Calabar bean extract as an
antidote to atropine poisoning. Anaesthesia 43:776–779
Nyiri G, Cserep C, Szabadits E, Mackie K, Freund TF (2005) CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136:811–822
Ogrodowczyk M, Dettlaff K, Jelinska A (2016) Beta-blockers: current state of knowledge and perspectives.
Mini Rev Med Chem 16:40–54
Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M (2012) Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 18:119–132
Osmond H, Smythies J (1952) Schizophrenia: a new approach. J Ment Sci 98:309–315
Pasternak GW, Pan YX (2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev
65:1257–1317
Paul K, Ruck CA, Bigwood J, Staples D, Ott J, Wasson RG (1979) Entheogens. J Psychedelic Drugs 11:
145–146
Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180
Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215
Pessah IN, Stambuk RA, Casida JE (1987) Ca2+−activated ryanodine binding: mechanisms of sensitivity
and intensity modulation by Mg2+, caffeine, and adenine nucleotides. Mol Pharmacol 31:232–238
Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR,
Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK (2007) Crystal structure of the human beta2
adrenergic G-protein-coupled receptor. Nature 450:383–387
Rivera-Oliver M, Diaz-Rios M (2014) Using caffeine and other adenosine receptor antagonists and agonists
as therapeutic tools against neurodegenerative diseases: a review. Life Sci 101:1–9
Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA (2003) In
vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307:138–145
Seeman P (2014) Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci 5:24–29
Shamon SD, Perez MI (2009) Blood pressure lowering efficacy of reserpine for primary hypertension.
Cochrane Database Syst Rev:CD007655
Shannon M, Neuman MI (2000) Yohimbine. Pediatr Emerg Care 16:49–50
Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder
CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for
schizophrenia. Am J Psychiatry 165:1033–1039
Simonson B, Morani AS, Ewald AW, Walker L, Kumar N, Simpson D, Miller JH, Prisinzano TE, Kivell BM (2015)
Pharmacology and anti-addiction effects of the novel kappa opioid receptor agonist Mesyl Sal B, a
potent and long-acting analogue of salvinorin A. Br J Pharmacol 172:515–531
Stacy M, Silver D (2008) Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Parkinsonism Relat Disord 14:85–92
Thiele A (2013) Muscarinic signaling in the brain. Annu Rev Neurosci 36:271–294
Tso PH, Wong YH (2003) Molecular basis of opioid dependence: role of signal regulation by G-proteins.
Clin Exp Pharmacol Physiol 30:307–316
Ulugol A (2014) The endocannabinoid system as a potential therapeutic target for pain modulation.
Balkan Med J 31:115–120
Vansal SS, Feller DR (1999) Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol 58:807–810
Vaughan RA, Foster JD (2013) Mechanisms of dopamine transporter regulation in normal and disease
states. Trends Pharmacol Sci 34:489–496
Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588–592
Yeh B (2012) The controlled substances act: regulatory requirements. Congressional Res Serv:1–17
Zajdel P, Bednarski M, Sapa J, Nowak G (2015) Ergotamine and nicergoline - facts and myths. Pharmacol
Rep: PR 67:360–363
Zhang N, Lian Z, Peng X, Li Z, Zhu H (2017) Applications of higenamine in pharmacology and medicine. J
Ethnopharmacol 196:242–252
Chapter 5 · GPCRs as Targets for Plant-Derived Drugs
5
Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181
Nickalls RW, Nickalls EA (1988) The first use of physostigmine in the treatment of atropine poisoning. A
translation of Kleinwachter’s paper entitled 'Observations on the effect of Calabar bean extract as an
antidote to atropine poisoning. Anaesthesia 43:776–779
Nyiri G, Cserep C, Szabadits E, Mackie K, Freund TF (2005) CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons. Neuroscience 136:811–822
Ogrodowczyk M, Dettlaff K, Jelinska A (2016) Beta-blockers: current state of knowledge and perspectives.
Mini Rev Med Chem 16:40–54
Ohno-Shosaku T, Tanimura A, Hashimotodani Y, Kano M (2012) Endocannabinoids and retrograde modulation of synaptic transmission. Neuroscientist 18:119–132
Osmond H, Smythies J (1952) Schizophrenia: a new approach. J Ment Sci 98:309–315
Pasternak GW, Pan YX (2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev
65:1257–1317
Paul K, Ruck CA, Bigwood J, Staples D, Ott J, Wasson RG (1979) Entheogens. J Psychedelic Drugs 11:
145–146
Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129–180
Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153:199–215
Pessah IN, Stambuk RA, Casida JE (1987) Ca2+−activated ryanodine binding: mechanisms of sensitivity
and intensity modulation by Mg2+, caffeine, and adenine nucleotides. Mol Pharmacol 31:232–238
Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR,
Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK (2007) Crystal structure of the human beta2
adrenergic G-protein-coupled receptor. Nature 450:383–387
Rivera-Oliver M, Diaz-Rios M (2014) Using caffeine and other adenosine receptor antagonists and agonists
as therapeutic tools against neurodegenerative diseases: a review. Life Sci 101:1–9
Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA (2003) In
vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 307:138–145
Seeman P (2014) Clozapine, a fast-off-D2 antipsychotic. ACS Chem Neurosci 5:24–29
Shamon SD, Perez MI (2009) Blood pressure lowering efficacy of reserpine for primary hypertension.
Cochrane Database Syst Rev:CD007655
Shannon M, Neuman MI (2000) Yohimbine. Pediatr Emerg Care 16:49–50
Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder
CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for
schizophrenia. Am J Psychiatry 165:1033–1039
Simonson B, Morani AS, Ewald AW, Walker L, Kumar N, Simpson D, Miller JH, Prisinzano TE, Kivell BM (2015)
Pharmacology and anti-addiction effects of the novel kappa opioid receptor agonist Mesyl Sal B, a
potent and long-acting analogue of salvinorin A. Br J Pharmacol 172:515–531
Stacy M, Silver D (2008) Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Parkinsonism Relat Disord 14:85–92
Thiele A (2013) Muscarinic signaling in the brain. Annu Rev Neurosci 36:271–294
Tso PH, Wong YH (2003) Molecular basis of opioid dependence: role of signal regulation by G-proteins.
Clin Exp Pharmacol Physiol 30:307–316
Ulugol A (2014) The endocannabinoid system as a potential therapeutic target for pain modulation.
Balkan Med J 31:115–120
Vansal SS, Feller DR (1999) Direct effects of ephedrine isomers on human beta-adrenergic receptor subtypes. Biochem Pharmacol 58:807–810
Vaughan RA, Foster JD (2013) Mechanisms of dopamine transporter regulation in normal and disease
states. Trends Pharmacol Sci 34:489–496
Wilson RI, Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588–592
Yeh B (2012) The controlled substances act: regulatory requirements. Congressional Res Serv:1–17
Zajdel P, Bednarski M, Sapa J, Nowak G (2015) Ergotamine and nicergoline - facts and myths. Pharmacol
Rep: PR 67:360–363
Zhang N, Lian Z, Peng X, Li Z, Zhu H (2017) Applications of higenamine in pharmacology and medicine. J
Ethnopharmacol 196:242–252
Chapter 5 · GPCRs as Targets for Plant-Derived Drugs